CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro

被引:72
作者
Salkowitz, JR
Bruse, SE
Meyerson, H
Valdez, H
Mosier, DE
Harding, CV
Zimmerman, PA
Lederman, MM
机构
[1] Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, AIDS Res Ctr, Sch Med, Dept Med,Div Infect Dis, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Cleveland, OH 44106 USA
[5] Univ Hosp Cleveland, Ctr AIDS Res, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA
[6] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[7] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
关键词
D O I
10.1016/S1521-6616(03)00147-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The common CCR5 promoter polymorphism at position -2459 (A/G) has been associated with differences in the rate of progression to AIDS, where HIV-1-infected individuals with the CCR5-2459 G/G genotype exhibit slower disease progression than those with the A/A genotype. Mechanisms underlying the relationship between these polymorphisms and disease progression are not known. Here through in vitro infection of peripheral blood mononuclear cells obtained from healthy Caucasian blood donors with macrophage-tropic HIV-1 isolates we observed low, medium, and high viral propagation in association with G/G, A/G, and A/A promoter genotypes, respectively. Flow cytometric analysis of unstimulated CD14+ monocytes from these same donors revealed a similar hierarchy of CCR5 receptor density in association with promoter genotypes. Finally, PBMC from persons with the G/G promoter polymorphism produced higher levels of P-chemokines after in vitro stimulation. Thus, the CCR5 -2459 (A/G) promoter polymorphism determines CCR5 expression and predicts the magnitude of HIV-1 propagation in vitro. These findings may provide important insight regarding the regulation of mechanisms that influence the rate of HIV-1 propagation and progression to AIDS. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 33 条
[21]   Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression:: the protection varies with duration of infection [J].
Mulherin, SA ;
O'Brien, TR ;
Ioannidis, JPA ;
Goedert, JJ ;
Buchbinder, SP ;
Coutinho, RA ;
Jamieson, BD ;
Meyer, L ;
Michael, NL ;
Pantaleo, G ;
Rizzardi, GP ;
Schuitemaker, H ;
Sheppard, HW ;
Theodorou, ID ;
Vlahov, D ;
Rosenberg, PS .
AIDS, 2003, 17 (03) :377-387
[22]   HIV-1 infection in a man homozygous for CCR5 Delta 32 [J].
OBrien, TR ;
Winkler, C ;
Dean, M ;
Nelson, JAE ;
Carrington, M ;
Michael, NL ;
White, GC .
LANCET, 1997, 349 (9060) :1219-1219
[23]   Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children [J].
Ometto, L ;
Bertorelle, R ;
Mainardi, M ;
Zanchetta, M ;
Tognazzo, S ;
Rampon, O ;
Ruga, E ;
Chieco-Bianchi, L ;
de Rossi, A .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (05) :814-818
[24]   Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals:: Association with low expression of CCR5 and high production of β-chemokines [J].
Paxton, WA ;
Liu, R ;
Kang, S ;
Wu, LJ ;
Gingeras, TR ;
Landau, NR ;
Mackay, CR ;
Koup, RA .
VIROLOGY, 1998, 244 (01) :66-73
[25]   Characterization of high-risk HIV-1 seronegative hemophiliacs [J].
Salkowitz, JR ;
Purvis, SF ;
Meyerson, H ;
Zimmerman, P ;
O'Brien, TR ;
Aledort, L ;
Eyster, ME ;
Hilgartner, M ;
Kessler, C ;
Konkle, BA ;
White, GC ;
Goedert, JJ ;
Lederman, MM .
CLINICAL IMMUNOLOGY, 2001, 98 (02) :200-211
[26]   Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene [J].
Samson, M ;
Libert, F ;
Doranz, BJ ;
Rucker, J ;
Liesnard, C ;
Farber, CM ;
Saragosti, S ;
Lapoumeroulie, C ;
Cognaux, J ;
Forceille, C ;
Muyldermans, G ;
Verhofstede, C ;
Burtonboy, G ;
Georges, M ;
Imai, T ;
Rana, S ;
Yi, YJ ;
Smyth, RJ ;
Collman, RG ;
Doms, RW ;
Vassart, G ;
Parmentier, M .
NATURE, 1996, 382 (6593) :722-725
[27]   Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression [J].
Smith, MW ;
Dean, M ;
Carrington, M ;
Winkler, C ;
Huttley, GA ;
Lomb, DA ;
Goedert, JJ ;
OBrien, TR ;
Jacobson, LP ;
Kaslow, R ;
Buchbinder, S ;
Vittinghoff, E ;
Vlahov, D ;
Hoots, K ;
Hilgartner, MW ;
OBrien, SJ .
SCIENCE, 1997, 277 (5328) :959-965
[28]  
Smith MW, 1997, LANCET, V350, P741, DOI 10.1016/S0140-6736(05)63551-9
[29]   Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression [J].
Tang, JM ;
Shelton, B ;
Makhatadze, NJ ;
Zhang, Y ;
Schaen, M ;
Louie, LG ;
Goedert, JJ ;
Seaberg, EC ;
Margolick, JB ;
Mellors, J ;
Kaslow, RA .
JOURNAL OF VIROLOGY, 2002, 76 (02) :662-672
[30]   Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy [J].
Valdez, H ;
Purvis, SF ;
Lederman, MM ;
Fillingame, M ;
Zimmerman, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (08) :734-734